CN1313846A - 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 - Google Patents
作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 Download PDFInfo
- Publication number
- CN1313846A CN1313846A CN99810019A CN99810019A CN1313846A CN 1313846 A CN1313846 A CN 1313846A CN 99810019 A CN99810019 A CN 99810019A CN 99810019 A CN99810019 A CN 99810019A CN 1313846 A CN1313846 A CN 1313846A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- naphthyl
- substituted
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical group CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 title abstract description 91
- 239000003112 inhibitor Substances 0.000 title abstract description 17
- 101150055276 ced-3 gene Proteins 0.000 title abstract description 11
- 239000004365 Protease Substances 0.000 title description 6
- 102000035195 Peptidases Human genes 0.000 title description 5
- 108091005804 Peptidases Proteins 0.000 title description 5
- 108010016626 Dipeptides Proteins 0.000 title description 3
- 210000004899 c-terminal region Anatomy 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 210000000056 organ Anatomy 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 208000037906 ischaemic injury Diseases 0.000 claims abstract description 8
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 238000002054 transplantation Methods 0.000 claims abstract description 5
- -1 2-benzoxazolyl group Chemical group 0.000 claims description 252
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 183
- 125000000217 alkyl group Chemical group 0.000 claims description 118
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 79
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000001624 naphthyl group Chemical group 0.000 claims description 59
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 42
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 32
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 230000035899 viability Effects 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 150000001975 deuterium Chemical group 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 125000004970 halomethyl group Chemical group 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 107
- 239000005950 Oxamyl Substances 0.000 abstract description 89
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 201
- 239000000243 solution Substances 0.000 description 172
- 239000011734 sodium Substances 0.000 description 119
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 86
- 238000003756 stirring Methods 0.000 description 85
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 73
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 68
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 64
- 239000007787 solid Substances 0.000 description 63
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 61
- 229910052757 nitrogen Inorganic materials 0.000 description 59
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 56
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 55
- 150000002500 ions Chemical class 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 125000002114 valyl group Chemical group 0.000 description 47
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 46
- 239000012299 nitrogen atmosphere Substances 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 41
- 239000012074 organic phase Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 36
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 32
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 32
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 26
- 125000006239 protecting group Chemical group 0.000 description 26
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 229960005261 aspartic acid Drugs 0.000 description 23
- 235000003704 aspartic acid Nutrition 0.000 description 23
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 23
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- 239000011347 resin Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 14
- 239000006260 foam Substances 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 13
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 13
- 238000000967 suction filtration Methods 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- MWPIIMNHWGOFBL-UHFFFAOYSA-N dichloromethane;toluene Chemical compound ClCCl.CC1=CC=CC=C1 MWPIIMNHWGOFBL-UHFFFAOYSA-N 0.000 description 11
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 11
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical group OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 10
- WQUVPVDYGDZFEQ-UHFFFAOYSA-N 1-(ethyliminomethylideneamino)-3-methylbutan-1-amine;hydrochloride Chemical compound Cl.CCN=C=NC(N)CC(C)C WQUVPVDYGDZFEQ-UHFFFAOYSA-N 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 10
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 9
- 229960003767 alanine Drugs 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- WVELHLIHMYYZAT-UHFFFAOYSA-N 2-(4-ethylphenoxy)acetic acid Chemical compound CCC1=CC=C(OCC(O)=O)C=C1 WVELHLIHMYYZAT-UHFFFAOYSA-N 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- ZCLSQRQRWNDNLV-UHFFFAOYSA-N acetic acid;dichloromethane;methanol Chemical compound OC.ClCCl.CC(O)=O ZCLSQRQRWNDNLV-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 238000005897 peptide coupling reaction Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 150000003462 sulfoxides Chemical class 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 150000004702 methyl esters Chemical class 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229960004441 tyrosine Drugs 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- 108010005843 Cysteine Proteases Proteins 0.000 description 6
- 102000005927 Cysteine Proteases Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 125000003431 oxalo group Chemical group 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 5
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 5
- 239000011698 potassium fluoride Substances 0.000 description 5
- 235000003270 potassium fluoride Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000007659 semicarbazones Chemical class 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- PFEVXIQTUGRDJO-UHFFFAOYSA-N CC(C)(C)OC(=O)C(N)CC(=O)COC1=C(F)C(F)=CC(F)=C1F Chemical compound CC(C)(C)OC(=O)C(N)CC(=O)COC1=C(F)C(F)=CC(F)=C1F PFEVXIQTUGRDJO-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- VWAAXMLHYUJXLH-UHFFFAOYSA-N dichloromethane;ethoxyethane;hexane Chemical compound ClCCl.CCOCC.CCCCCC VWAAXMLHYUJXLH-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 235000013930 proline Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XYXYXSKSTZAEJW-VIFPVBQESA-N (2s)-2-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 XYXYXSKSTZAEJW-VIFPVBQESA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101150047706 CASP6 gene Proteins 0.000 description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZHZZWIQPCAMTIM-UHFFFAOYSA-N [C]1=CC=CC2=CC=CC=C12 Chemical compound [C]1=CC=CC2=CC=CC=C12 ZHZZWIQPCAMTIM-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical group 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 235000008729 phenylalanine Nutrition 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- CTMSODIITHUVBD-GGEAOGJYSA-N tert-butyl (3S,5S)-2,5-diamino-3-[1-hydroxy-2-(2,3,5,6-tetrafluorophenoxy)ethyl]-4-oxohexanoate Chemical compound C(C)(C)(C)OC(C([C@@H](C(COC1=C(C(=CC(=C1F)F)F)F)O)C([C@@H](N)C)=O)N)=O CTMSODIITHUVBD-GGEAOGJYSA-N 0.000 description 3
- HHEDTMQFVNVGQF-RGURZIINSA-N tert-butyl (3s)-3-amino-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound CC(C)(C)OC(=O)C[C@H](N)C(O)COC1=C(F)C(F)=CC(F)=C1F HHEDTMQFVNVGQF-RGURZIINSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- PBYIIRLNRCVTMQ-UHFFFAOYSA-N 2,3,5,6-tetrafluorophenol Chemical compound OC1=C(F)C(F)=CC(F)=C1F PBYIIRLNRCVTMQ-UHFFFAOYSA-N 0.000 description 2
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- QCOPKGSDOIQRND-ZBOMDNBJSA-N CC1=CC=C(C=C1)S(=O)(=O)O.C(C)(C)(C)OC(C(C(C(CF)O)C([C@@H](N)CC(C)C)=O)N)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O.C(C)(C)(C)OC(C(C(C(CF)O)C([C@@H](N)CC(C)C)=O)N)=O QCOPKGSDOIQRND-ZBOMDNBJSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- ZTPIMGZNUMFPGQ-UHFFFAOYSA-N amino 4-oxobutanoate Chemical compound NOC(=O)CCC=O ZTPIMGZNUMFPGQ-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- LJWKFGGDMBPPAZ-UHFFFAOYSA-N ethoxyethane;toluene Chemical compound CCOCC.CC1=CC=CC=C1 LJWKFGGDMBPPAZ-UHFFFAOYSA-N 0.000 description 2
- KISPUTPAKVZNBI-UHFFFAOYSA-N ethyl 2,3-dihydro-1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)CC2=C1 KISPUTPAKVZNBI-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- VVVJBDNHHIBWTD-UHFFFAOYSA-N n,n-dimethylformamide;pyrrolidine Chemical compound CN(C)C=O.C1CCNC1 VVVJBDNHHIBWTD-UHFFFAOYSA-N 0.000 description 2
- WSZXJUNYWNMAOE-UHFFFAOYSA-N n-phenyl-2-(2h-tetrazol-5-yl)acetamide Chemical compound C=1C=CC=CC=1NC(=O)CC1=NN=NN1 WSZXJUNYWNMAOE-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FXHXDVSVXUUFFK-MJVOBMLWSA-N tert-butyl (3S,5S)-2,5-diamino-3-[1-hydroxy-2-(2,3,5,6-tetrafluorophenoxy)ethyl]-6-methyl-4-oxoheptanoate Chemical compound C(C)(C)(C)OC(C([C@@H](C(COC1=C(C(=CC(=C1F)F)F)F)O)C([C@@H](N)C(C)C)=O)N)=O FXHXDVSVXUUFFK-MJVOBMLWSA-N 0.000 description 2
- YWLHJKXAMBKLDM-UHFFFAOYSA-N tert-butyl 2-amino-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound CC(C)(C)OC(=O)C(N)CC(O)COC1=C(F)C(F)=CC(F)=C1F YWLHJKXAMBKLDM-UHFFFAOYSA-N 0.000 description 2
- KXOLECFIQWMQMG-UHFFFAOYSA-N tert-butyl 2-amino-5-bromo-4-oxopentanoate Chemical compound CC(C)(C)OC(=O)C(N)CC(=O)CBr KXOLECFIQWMQMG-UHFFFAOYSA-N 0.000 description 2
- AECNGSKDJGEXJS-UHFFFAOYSA-N tert-butyl 2-amino-5-fluoro-4-oxopentanoate Chemical compound C(C)(C)(C)OC(C(CC(CF)=O)N)=O AECNGSKDJGEXJS-UHFFFAOYSA-N 0.000 description 2
- GAOCYGMWQJTKPG-UHFFFAOYSA-N tert-butyl 3-amino-5-fluoro-4-hydroxypentanoate Chemical compound CC(C)(C)OC(=O)CC(N)C(O)CF GAOCYGMWQJTKPG-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000004953 trihalomethyl group Chemical group 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- JZKJDOXJTPNRNK-SECBINFHSA-N (2R)-2-amino-2-phenoxypropanoic acid Chemical compound O(C1=CC=CC=C1)[C@](N)(C)C(=O)O JZKJDOXJTPNRNK-SECBINFHSA-N 0.000 description 1
- QIGAECVGPWRCHY-ZETCQYMHSA-N (2r)-2-amino-2,3,3-trimethylbutanoic acid Chemical compound CC(C)(C)[C@@](C)(N)C(O)=O QIGAECVGPWRCHY-ZETCQYMHSA-N 0.000 description 1
- PAORVUMOXXAMPL-VIFPVBQESA-N (2r)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-VIFPVBQESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- MSJVZYZBQGBEQX-BYPYZUCNSA-N (2s)-2-(ethenylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=C MSJVZYZBQGBEQX-BYPYZUCNSA-N 0.000 description 1
- HKZCDMUOAAWVBO-YFKPBYRVSA-N (2s)-2-(furan-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=COC=1 HKZCDMUOAAWVBO-YFKPBYRVSA-N 0.000 description 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- WRQSUCJAKAMYMQ-YFKPBYRVSA-N (2s)-2-(thiophen-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=CSC=1 WRQSUCJAKAMYMQ-YFKPBYRVSA-N 0.000 description 1
- JOWKLGMNVUYQGV-INIZCTEOSA-N (2s)-2-[cyclohexyl(9h-fluoren-9-ylmethoxycarbonyl)amino]propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N([C@@H](C)C(O)=O)C1CCCCC1 JOWKLGMNVUYQGV-INIZCTEOSA-N 0.000 description 1
- RXZQHZDTHUUJQJ-LURJTMIESA-N (2s)-2-amino-3-(furan-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CO1 RXZQHZDTHUUJQJ-LURJTMIESA-N 0.000 description 1
- LPBSHGLDBQBSPI-YFKPBYRVSA-N (2s)-2-amino-4,4-dimethylpentanoic acid Chemical compound CC(C)(C)C[C@H](N)C(O)=O LPBSHGLDBQBSPI-YFKPBYRVSA-N 0.000 description 1
- LOVUSASSMLUWRR-REOHCLBHSA-N (2s)-2-hydrazinylpropanoic acid Chemical compound NN[C@@H](C)C(O)=O LOVUSASSMLUWRR-REOHCLBHSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- QZHGMNYYHDNFPX-UHFFFAOYSA-N 1,3-bis(2,3,4,5-tetrafluorophenoxy)propan-2-one Chemical compound FC1=C(F)C(F)=CC(OCC(=O)COC=2C(=C(F)C(F)=C(F)C=2)F)=C1F QZHGMNYYHDNFPX-UHFFFAOYSA-N 0.000 description 1
- UXBIXOXDACBTDG-UHFFFAOYSA-N 1-adamantyl radical Chemical compound C1C(C2)CC3C[C]1CC2C3 UXBIXOXDACBTDG-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical group OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- UTIMBUCRNZURQB-UHFFFAOYSA-N 2-(propylamino)propanoic acid Chemical compound CCCNC(C)C(O)=O UTIMBUCRNZURQB-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DGPWASIVWNADCJ-UHFFFAOYSA-N 2-[4-(2-azaniumylethyl)phenoxy]acetate Chemical compound NCCC1=CC=C(OCC(O)=O)C=C1 DGPWASIVWNADCJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YWQDZLIVCPYGGO-UHFFFAOYSA-N 2-amino-5-bromo-4-oxopentanoic acid Chemical compound OC(=O)C(N)CC(=O)CBr YWQDZLIVCPYGGO-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- XCTQPMCULSZKLT-UHFFFAOYSA-N 2-cyano-n-phenylacetamide Chemical compound N#CCC(=O)NC1=CC=CC=C1 XCTQPMCULSZKLT-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- NYPYHUZRZVSYKL-ZETCQYMHSA-N 3,5-diiodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-ZETCQYMHSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OORABVZQDNHNHF-UHFFFAOYSA-N CC(CC(N)N=C=N)C Chemical compound CC(CC(N)N=C=N)C OORABVZQDNHNHF-UHFFFAOYSA-N 0.000 description 1
- UBCFWMUJGWCNKJ-BYPYZUCNSA-N CON(C)C(=O)C[C@H](N)C(O)=O Chemical compound CON(C)C(=O)C[C@H](N)C(O)=O UBCFWMUJGWCNKJ-BYPYZUCNSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LJCWONGJFPCTTL-SSDOTTSWSA-N D-4-hydroxyphenylglycine Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC=C(O)C=C1 LJCWONGJFPCTTL-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010069384 Ischaemic nephropathy Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical class OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- WRFPVMFCRNYQNR-ZETCQYMHSA-N L-o-tyrosine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC=CC=C1O WRFPVMFCRNYQNR-ZETCQYMHSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CEVMHNYGQHSFTH-UHFFFAOYSA-N O=CCC(N)C(O)=NNC(N)=O Chemical compound O=CCC(N)C(O)=NNC(N)=O CEVMHNYGQHSFTH-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OSGZDPFBQZONOZ-UHFFFAOYSA-N [4-amino-5-[(2-methylpropan-2-yl)oxy]-2,5-dioxopentyl] 2,6-dichlorobenzoate Chemical compound CC(C)(C)OC(=O)C(N)CC(=O)COC(=O)C1=C(Cl)C=CC=C1Cl OSGZDPFBQZONOZ-UHFFFAOYSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 1
- FMFSVZQZWVMVKB-UHFFFAOYSA-N [C]1=CN=CC=N1 Chemical compound [C]1=CN=CC=N1 FMFSVZQZWVMVKB-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- UOIFTOBIGNZZSO-UHFFFAOYSA-N acetic acid;ethyl acetate;hexane Chemical compound CC(O)=O.CCCCCC.CCOC(C)=O UOIFTOBIGNZZSO-UHFFFAOYSA-N 0.000 description 1
- MLPSGIDDQNVPBO-UHFFFAOYSA-N acetic acid;formaldehyde;oxolane;2,2,2-trifluoroacetic acid Chemical compound O=C.CC(O)=O.C1CCOC1.OC(=O)C(F)(F)F MLPSGIDDQNVPBO-UHFFFAOYSA-N 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- AYGXHRXZVUYYPT-UHFFFAOYSA-N anisole;dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F.COC1=CC=CC=C1 AYGXHRXZVUYYPT-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-O bis(2-hydroxyethyl)azanium Chemical compound OCC[NH2+]CCO ZBCBWPMODOFKDW-UHFFFAOYSA-O 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- PXSFGMATQMURKO-UHFFFAOYSA-N dichloromethane;methanol;propan-2-one Chemical compound OC.ClCCl.CC(C)=O PXSFGMATQMURKO-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- BEQVQKJCLJBTKZ-UHFFFAOYSA-N diphenylphosphinic acid Chemical compound C=1C=CC=CC=1P(=O)(O)C1=CC=CC=C1 BEQVQKJCLJBTKZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000010380 endocervicitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- VTNFLVJEOPKVIC-PPHPATTJSA-N ethyl (2s)-2,3-dihydro-1h-indole-2-carboxylate;hydrochloride Chemical compound Cl.C1=CC=C2N[C@H](C(=O)OCC)CC2=C1 VTNFLVJEOPKVIC-PPHPATTJSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- WEVKQMBWAPJFSP-UHFFFAOYSA-N ethyl acetate;2-pyridin-2-ylacetic acid;hydrate Chemical compound O.CCOC(C)=O.OC(=O)CC1=CC=CC=N1 WEVKQMBWAPJFSP-UHFFFAOYSA-N 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- WVRVSXCLRWNWQK-UHFFFAOYSA-N methyl 2-[4-(2-aminoethyl)phenoxy]acetate;hydrochloride Chemical compound Cl.COC(=O)COC1=CC=C(CCN)C=C1 WVRVSXCLRWNWQK-UHFFFAOYSA-N 0.000 description 1
- AEVHVVDLIHWAGR-UHFFFAOYSA-N methyl 2-amino-2-oxoacetate Chemical compound COC(=O)C(N)=O AEVHVVDLIHWAGR-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ALJOZEHGARQUNR-ZOWNYOTGSA-N n-cyclohexylcyclohexanamine;(2s)-2-[cyclohexyl(phenylmethoxycarbonyl)amino]propanoic acid Chemical compound C1CCCCC1NC1CCCCC1.C=1C=CC=CC=1COC(=O)N([C@@H](C)C(O)=O)C1CCCCC1 ALJOZEHGARQUNR-ZOWNYOTGSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- IQQDNMHUOLMLNJ-UHFFFAOYSA-N quinolin-3-ol Chemical compound C1=CC=CC2=CC(O)=CN=C21 IQQDNMHUOLMLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000010512 small scale reaction Methods 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- ZOXQCJYKNMOVRO-JKIOLJMWSA-N tert-butyl (3S,5S)-2,5-diamino-N-carbamoyl-3-formyl-7-methyl-4-oxooctanehydrazonate Chemical compound CC(C)C[C@H](N)C(=O)[C@H](C=O)C(N)C(OC(C)(C)C)=NNC(N)=O ZOXQCJYKNMOVRO-JKIOLJMWSA-N 0.000 description 1
- RTBHEJSAOKPNHQ-ZHEBCZLYSA-N tert-butyl (3S,5S)-2-amino-5-(cyclohexylamino)-3-[1-hydroxy-2-(2,3,5,6-tetrafluorophenoxy)ethyl]-4-oxohexanoate Chemical compound C(C)(C)(C)OC(C([C@@H](C(COC1=C(C(=CC(=C1F)F)F)F)O)C([C@@H](NC1CCCCC1)C)=O)N)=O RTBHEJSAOKPNHQ-ZHEBCZLYSA-N 0.000 description 1
- GEPHUBSBUNCTSV-VELWFJCASA-N tert-butyl (3s)-3-[[(2s)-2-(cyclohexylamino)propanoyl]amino]-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)COC=1C(=C(F)C=C(F)C=1F)F)C1CCCCC1 GEPHUBSBUNCTSV-VELWFJCASA-N 0.000 description 1
- OYPHALZLRMZFAJ-BHWOMJMDSA-N tert-butyl (3s)-3-[[2-(cyclohexylamino)acetyl]amino]-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C(O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)CNC1CCCCC1 OYPHALZLRMZFAJ-BHWOMJMDSA-N 0.000 description 1
- TWYSODGJQICHJK-UHFFFAOYSA-N tert-butyl 2-amino-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)C(N)CC=O TWYSODGJQICHJK-UHFFFAOYSA-N 0.000 description 1
- COXUQTRSJXNTSH-UHFFFAOYSA-N tert-butyl 2-amino-5-diphenylphosphoryloxy-4-oxopentanoate Chemical compound C(C)(C)(C)OC(C(CC(COP(=O)(C1=CC=CC=C1)C1=CC=CC=C1)=O)N)=O COXUQTRSJXNTSH-UHFFFAOYSA-N 0.000 description 1
- LQAJPDUYWHCQFF-UHFFFAOYSA-N tert-butyl 4-hydroxy-2-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound CC(C)(C)OC(=O)C(CC(O)C)OC1=C(F)C(F)=CC(F)=C1F LQAJPDUYWHCQFF-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3264—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Abstract
Description
实施例序号 | mICEIC50(μM) | CPP32IC50(μM) | MCH-2IC50(μM) | MCH-3IC50(μM) | MCH-5IC50(μM) |
1 | 0.027 | 0.010 | 1.50 | 0.267 | 0.179 |
112 | 0.059 | 1.38 | 3.53 | 1.13 | 0.322 |
参照 | 0.064 | 47.0 | >10 | >10 | 2.96 |
分析 | 实施例号 |
mICE | 3-8,10-13,15-16,18-19,28-35,40,4243,45-49,55-61,63-64,66,72,75-79,81-82,84,89,91-95,102-110B |
CPP32 | 3-13,15-19,29-35,37-38,40-43,46-49,52,55-61,64-66,72,76,103-104,106 |
MCH-2 | 3-7,10-13,15-16,18-19,28-35,37-43,45-53,55-66,72-75,78,83-84,91-95,102-108,110A-110B |
MCH-5 | 3-8,10-13,15-16,18-19,28-35,37-43,45-66,72,74-79,81-84,89-95,102-110B |
分析 | 实施例号 |
mICE | 3-8,10-12.15-16,33-34,42,46,49,55-57,78-79,82,93,95,103- |
108 | |
MCH-2 | 4,29,38,42-43,46,55,64,108 |
MCH-5 | 3-7,10-11,15-16,28,33-34,38,42-43,45-49,55-59,64,72,75,78-79,82,92-93,95,103-104,106-108.110A-110B |
MS(ES) | |||||
Ex. | B | 式 | MW | 正离子的 | 负离子的 |
5 | CH2O(2,6-diF-Ph) | C28H27F2N3O7 | 555.53 | 578(M+Na) | 554(M-H) |
6 | CH2O(2,4,6-三F-Ph) | C28H26F3N3O7 | 573.52 | 596(M+Na) | 572(M-H) |
7 | CH2O(2,3,5,6-四F-Ph) | C28H25F4N3O7 | 591.51 | 614(M+Na) | 590(M-H) |
8 | CH2O(6-Me-2-吡喃酮-4-基) | C28H29N3O9 | 551.55 | 574(M+Na) | 550(M-H) |
9 | CH2O(2-Ph-5,6-苯并吡喃-4-酮-3-基) | C32H33N3O9 | 663.68 | 686(M+Na) | 662(M-H) |
10 | CH2OPO(Me)Ph | C29H32N3O8P | 581.56 | 582(M+H)604(M+Na) | 580(M-H)694(M+TFA) |
11 | CH2OPOPh2 | C34H34N3O8P | 643.63 | 666(M+Na) | 642(M-H) |
12 | CH2O(2-CF3-嘧啶-4-基) | C27H26F3N5O7 | 589.53 | 612(M+Na) | 588(M-H) |
13 | CH2O(5-CO2Me-异噁唑-3-基) | C27H28N4O10 | 568.54 | 591(M+Na) | 567(M-H) |
14 | CH2OPO(Me)(1-萘基) | C33H34N3O8P | 631.62 | 654(M+Na) | 630(M-H)744(M+TFA) |
MS(ES) | |||||
Ex. | B | 式 | MW | 正离子的 | 负离子的 |
16 | CH2OCO(2,6-diCl-Ph) | C30H29Cl2N3O8 | 630.48 | 652/654(M+Na) | 628/630(M-H) |
17 | CH2O(2,4,6-三F-Ph) | C29H28F3N3O7 | 587.55 | 610(M+Na) | 586(M-H) |
18 | CH2O(2,3,5,6-四F-Ph) | C29H27F4N3O7 | 605.54 | 628(M+Na) | 604(M-H) |
19 | CH2OPO(Me)Ph | C30H34N3O8P | 595.59 | 596(M+H)618(M+Na) | 594(M-H)708(M+TFA) |
MS(ES) | ||||||
Ex. | R1 | B | 式 | MW | 正离子的 | 负离子的 |
20 | (2-Ph)Ph | CH2O(2-F-Ph) | C28H26FN3O7 | 535.53 | 558(M+Na) | 534(M-H) |
21 | (2-Ph)Ph | CH2OCO(2,6-di-Cl-Ph) | C29H25Cl2N3O8 | 614.44 | 652/654(M+K) | 612/614(M-H) |
22 | (2-Ph)Ph | CH2OPOPh2 | C34H32N3O8P | 641.61 | 664(M+Na)680(M+K) | 640(M-H) |
23 | (2-t-Bu)Ph | CH2O(2-F-Ph) | C26H30FN3O7 | 515.54 | 516(M+H)538(M+Na)554(M+K) | 514(M-H) |
24 | (2-t-Bu)Ph | CH2OPOPh2 | C32H36N3O8P | 621.63 | 644(M+Na)666(M+K) | 620(M-H) |
25 | 1-萘基-CH2 | CH2O(2,3,5,6-四·F-Ph) | C27H23F4N3O7 | 577.48 | 600(M+Na)616(M+K) | 576(M-H) |
26 | 1-萘基-CH2 | CH2OCO(2,6-di-Cl-Ph) | C28H25Cl2N3O8 | 602.42 | 624/626(M+Na)640/642(M+K) | 600/602(M-H)714/716(M+TFA) |
27 | 1-萘基-CH2 | CH2OPOPh2 | C33H32N3O8P | 629.60 | 652(M+Na)668(M+K) | 628(M-H) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
29 | PhCH2 | C25H25F4N3O7 | 555.48 | 556(M+H)578(M+Na) | 554(M-H) |
30 | Ph(CH2)2 | C26H27F4N3O7 | 569.51 | 592(M+Na) | 568(M-H) |
31 | Ph2CH | C31H29F4N3O7 | 631.58 | 654(M+Na) | 630(M-H) |
32 | Ph | C24H23F4N3O7 | 541.46 | 564(M+Na) | 540(M-H) |
33 | (2-Ph)Ph | C30H27F4N3O7 | 617.55 | 640(M+Na) | 616(M-H)730(M+TFA) |
34 | (2-PhCH2)Ph | C31H29F4N3O7 | 631.58 | 654(M+Na) | 630(M-H) |
35 | (3-PhO)Ph | C30H27F4N3O8 | 633.55 | 634(M+H)656(M+Na) | 632(M-H) |
36 | 4-Cl-1-萘基 | C28H24ClF4N3O7 | 625.96 | 648/650(M+Na) | 624/626(M-H) |
37 | 2-蒽基 | C32H27F4N3O7 | 641.57 | 642(M+H) | 640(M-H) |
38 | 2-苯并咪唑基 | C25H23F4N5O7 | 581.48 | 582(M+H)604(M+Na) | 580(M-H) |
39 | 1-金刚烷基 | C28H33F4N3O7 | 599.58 | 600(M+H) | 598(M-H) |
40 | (2-F)Ph | C24H22F5N3O7 | 559.45 | 582(M+Na) | 558(M-H)672(M+TFA) |
41 | (4-F)Ph | C24H22F5N3O7 | 559.45 | 582(M+Na) | 558(M-H)672(M++TFA) |
42 | (2-CF3)Ph | C25H22F7N3O7 | 609.45 | 632(M+Na) | 608(M-H)722(M+TFA) |
43 | (2-t-Bu)Ph | C28H31F4N3O7 | 597.56 | 620(M+Na) | 596(M-H)710(M+TFA) |
44 | (4-n-庚基)Ph | C31H37F4N3O7 | 639.64 | 662(M+Na) | 638(M-H) |
45 | (2-CH3O)Ph | C25H25F4N3O8 | 571.48 | 594(M+Na) | 570(M-H) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
46 | (2-PhO)ph | C30H27F4N3O8 | 633.55 | 656(M+Na) | 632(M-H)746(M+TFA) |
47 | 2-萘基 | C28H25F4N3O7 | 591.51 | 614(M+Na) | 590(M-H) |
48 | 5,6,7,8-四氢-1-萘基 | C28H29F4N3O7 | 595.55 | 618(M+Na) | 594(M-H) |
49 | 1-蒽基 | C32H27F4N3O7 | 641.57 | 664(M+Na) | 640(M-H) |
50 | 2-吡啶基 | C23H22F4N4O7 | 542.44 | 543(M+H) | 541(M-H) |
51 | 4-吡啶基 | C23H22F4N4O7 | 542.44 | 543(M+H) | 541(M-H) |
52 | 2,3,5,6-四氟-4-吡啶基 | C23H18F8N4O7 | 614.40 | 615(M+H) | 613(M-H) |
53 | 2-吡嗪基 | C22H21F4N5O7 | 543.43 | 544(M+H) | 542(M-H) |
54 | 1,2,3,4-四氢-1-萘基 | C28H29F4N3O7 | 595.55 | 596(M+H)618(M+Na)634(M+K) | 594(M-H)708(M+TFA) |
55 | (2-Cl)Ph | C24H22ClF4N3O7 | 575.90 | 598/600(M+Na) | 574/576(M-H) |
56 | (2-Br)Ph | C24H22BrF4N3O7 | 620.35 | 644/642(M+Na) | 620/618(M-H)734/732(M+TFA) |
57 | (2-I)Ph | C24H22F4IN3O7 | 667.35 | 690(M+Ma)706(M+K) | 666(M-H)780(M+TFA) |
58 | (2,6-di-F)Ph | C24H22F6N3O7 | 577.44 | 600(M+Na) | 576(M-H)690(M+TFA) |
59 | (2,5-di-t-Bu)Ph | C32H39F4N3O7 | 653.67 | 654(M+H)676(M+Na)692(M+K) | 652(M-H)688(M+Cl)766(M+TFA) |
60 | 5-二氢化茚基 | C27H27F4N3O7 | 581.52 | 604(M+Na)620(M+K) | 580(M-H)694(M+TFA) |
61 | (3,4,5-三-MeO)PhCH2 | C28H31F4N3O10 | 645.56 | 646(M+H)668(M+Na)684(M+K) | 644(M-H) |
62 | 甲基 | C19H21F4N3O7 | 479.38 | 502(M+Na) | 478(M-H)592(M+TFA) |
63 | n-庚基 | C25H33F4N3O7 | 563.55 | 586(M+Na)602(M+K) | 562(M-H)676(M+TFA) |
64 | t-辛基 | C26H35F4N3O7 | 577.57 | 600(M+Na) | 576(M-H) |
65 | 环己基 | C24H29F4N3O7 | 547.50 | 548(M+H)570(M+Na)586(M+K) | 546(M-H)660(M+TFA) |
66 | 5-Ph-3-吡唑基 | C27H25F4N5O7 | 607.52 | 630(M+Na)646(M+K) | 606(M-H) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
67 | (2-F-4-I)Ph | C24H21F5IN3O7 | 685.34 | 686(M+H)708(M+Na)724(M+K) | 684(M-H)720(M+Cl) |
68 | (2,3,4,5-四-F)Ph | C24H19F8N3O7 | 613.41 | 614(M+H)636(M+Na)652(M+K) | 612(M-H)726(M+TFA) |
69 | (2,3,4,6-四-F)Ph | C24H19F8N3O7 | 613.41 | 614(M+H)636(M+Na)652(M+K) | 612(M-H)726(M+TFA) |
70 | (2,3,5,6-四-Cl)Ph | C24H19Cl4F4N3O7 | 679.23 | 700/702/704(M+Na)716 /718/720(M+K) | 676/678/680(M-H)790/792/794(M+TFA) |
71 | (2,3,4,5,6-五F)Ph | C24H18F9N3O7 | 631.40 | 654(M+Na)670(M+K) | 630(M-H)666(M+Cl) |
72 | Ph2N | C30H28F4N4O7 | 632.57 | 633(M+H)655(M+Na) | 631(M-H)745(M+TFA) |
73 | PHCH2(Ph)N | C31H30F4N4O7 | 646.59 | 647(M+H)669(M+Na)685(M+K) | 645(M-H)681(M+Cl) |
74 | PhCH2O | C25H25F4N3O7 | 571.48 | 594(M+Na) | 570(M-H)684(M+TFA) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
76 | (2-CF3)Ph | C23H18F7N3O7 | 581.40 | 604(M+Na) | 580(M-H) |
77 | (2-Ph)Ph | C28H23F4N3O7 | 589.50 | 612(M+Na) | 588(M-H) |
78 | (2-PhCH2)Ph | C29H25F4N3O7 | 603.53 | 604(M+H) | 602(M-H) |
79 | (2-PhO)Ph | C28H23F4N3O8 | 605.50 | 628(M+Na) | 604(M-H) |
80 | (3-PhO)Ph | C28H23F4N3O8 | 605.50 | 628(M+Na) | 604(M-H) |
81 | 5,6,7,8-四氢-1-萘基 | C26H25F4N3O7 | 567.49 | 590(M+Na) | 566(M-H) |
82 | 1-萘基 | C26H21F4N3O7 | 563.46 | 586(M+Na)608(M+K) | 562(M-H) |
83 | Ph | C22H19F4N3O7 | 513.40 | 552(M+K) | 512(M-H) |
84 | (2,6-di-F)Ph | C22H17F6N3O7 | 549.38 | 572(M+Na) | 548(M-H)662(M+TFA) |
85 | (4-Ph)Ph | C28H23F4N3O7 | 589.50 | - | 588(M-H) |
86 | (4-MeO)Ph | C23H21F4N3O8 | 543.43 | 582(M+K) | 542(M-H) |
87 | Ph2CH | C29H25F4N3O7 | 603.53 | 642(M+K) | 602(M-H) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
89 | (2-Ph)Ph | C34H33F4N3O7 | 671.64 | 672(M+H)694(M+Na) | 670(M-H)784(M+TFA) |
90 | (2-PhCH2)Ph | C35H35F4N3O7 | 685.67 | 708(M+Na) | 684(M-H)798(M+TFA) |
91 | 1-萘基 | C32H31F4N3O7 | 645.61 | 668(M+Na) | 644(M-H)758(M+TFA) |
MS(ES) | ||||||
Ex. | R1 | B | 式 | MW | 正离子的 | 负离子的 |
93 | 5,6,7,8-四氢-1-萘基 | CH2O(2,3,5,6-tetra-F-Ph) | C32H35F4N3O7 | 649.64 | 672(M+Na) | 648(M-H) |
94 | 5,6,7,8-四氢-1-萘基 | CH2OPO(Me)Ph | C33H42N3O8P | 639.68 | 662(M+Na) | 638(M-H)752(M+TFA) |
95 | 5,6,7,8-四氢-1-萘基 | CH2OpOPh2 | C38H44N3O8P | 701.75 | 724(M+Na)740(M+K) | 700(M+H) |
96 | (2-PhCH2)Ph | CH2OPO(Me)Ph | C36H42N3O8P | 675.72 | 698(M+Na)714(M+K) | 674(M-H)788(M+TFA) |
97 | (2-PhCH2)Ph | CH2OPOPh2 | C41H44N3O8P | 737.79 | 760(M+Na)776(M+K) | 736(M-H)850(M+TFA) |
98 | (2-Ph)Ph | CH2OPO(Me)Ph | C40H42N3O8P | 661.68 | 684(M+Na)700(M+K) | 660(M-H)774(M+TFA) |
99 | (2-Ph)Ph | CH2OPOPh2 | C35H40N3O8P | 723.75 | 746(M+Na)762(M+K) | 722(M-H)836(M+TFA) |
MS(ES) | |||||
Ex. | A | 式 | MW | 正离子的 | 负离子的 |
103 | 正亮氨酸 | C29H27F4N3O7 | 605.54 | 628(M+Na)644(M+K) | 604(M-H)640(M+Cl)718(M+TFA) |
104 | 叔丁基甘氨酸 | C29H27F4N3O7 | 605.54 | 606(M+H)628(M+Na)644(M+K) | 604(M-H)640(M+Cl)718(M+TFA) |
105 | 叔丁基丙氨酸 | C20H29F4N3O7 | 619.57 | 620(M+H)642(M+Na)658(M+K) | 618(M-H)732(M+TFA) |
106 | 苯基甘氨酸 | C31H23F4N3O7 | 625.53 | 626(M+H)648(M+Na)664(M+K) | 624(M-H)660(M+Cl)738(M+TFA) |
107 | 丙基丙氨酸 | C32H25F4N3O7 | 639.56 | 640(M+H)662(M+Na)678(M+K) | 638(M-H)674(M+Cl)712(M+TFA) |
108 | 高苯基丙氨酸 | C33H27F4N3O7 | 653.59 | 654(M+H)676(M+Na)692(M+K) | 652(M-H)688(M+Cl)766(M+TFA) |
109 | 1-氨基环戊烷羧基 | C29H25F4N3O7 | 603.53 | 626(M+Na)642(M+K) | 602(M-H) |
MS(ES) | |||||
Ex. | R1 | 式 | MW | 正离子的 | 负离子的 |
114 | Ph | C17H21N3O6 | 363.37 | 386(M+Na)402(M+K) | 362(M-H) |
115 | PhCH2 | C18H23N3O6 | 377.40 | 400(M+Na) | 376(M-H) |
116 | Ph(CH2)2 | C19H25N3O6 | 391.42 | 414(M+Na)430(M+K) | 390(M-H)504(M+TFA) |
117 | (2-CF3)Ph | C18H20F3N3O6 | 431.37 | 454(M+Na) | 430(M-H) |
118 | (2-t-Bu)Ph | C21H29N3O6 | 419.48 | 442(M+Na)458(M+K) | 418(M-H)532(M+TFA) |
119 | (2-Ph)Ph | C23H25N3O6 | 439.47 | 462(M+Na)478(M+K) | 438(M-H)552(M+TFA) |
120 | (2-PhCH2)Ph | C24H27N3O6 | 453.49 | 476(M+Na)492(M+K) | 452(M-H)566(M+TFA) |
121 | (2-PhO)Ph | C23H25N3O7 | 455.47 | 478(M+Na)494(M+K) | 454(M-H)568(M+TFA) |
122 | 2-萘基 | C21H23N3O6 | 413.43 | 436(M+Na)452(M+K) | 412(M-H)526(M+TFA) |
123 | 1-萘基 | C21H23N3O6 | 413.43 | 436(M+Na)452(M+K) | 412(M-H)526(M+TFA) |
124 | 4-Cl-1-萘基 | C21H22ClN3O6 | 447.87 | 470/472(M+Na)486/488(M+K) | 446/448(M-H) |
125 | 5,6,7,8-四氢-1-萘基 | C21H27N3O6 | 417.46 | 440(M+Na)456(M+K) | 416(M-H)530(M+TFA) |
126 | 1,2,3,4-四氢-1-萘基 | C21H27N3O6 | 417.46 | 440(M+Na)456(M+K) | 416(M-H)530(M+TFA) |
127 | (1-萘基)CH2 | C22H25N3O6 | 427.46 | 450(M+Na)466(M+K) | 426(M-H)540(M+TFA) |
Claims (29)
- A是天然的或非天然的式Ⅱa-i的氨基酸:B是氢原子、氘原子、烷基、环烷基、苯基、取代的苯基、萘基、取代的萘基、2-苯并噁唑基、取代的2-噁唑基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)、(CH2)n(取代的1-或2-萘基)、(CH2)n(杂芳基)、(CH2)n(取代的杂芳基)、卤代甲基、CO2R12、CONR13R14、CH2ZR15、CH2OCO(芳基)、CH2OCO(杂芳基)或CH2OPO(R16)R17,其中Z是氧或硫原子,或者B是式Ⅲa-c的基团:R1是烷基、环烷基、(环烷基)烷基、苯基、取代的苯基、苯基烷基、取代的苯基烷基、萘基、取代基的萘基、(1-或2-萘基)烷基、杂芳基、取代的杂芳基、(杂芳基)烷基、取代的(杂芳基)烷基、R1a(R1b)N或R1cO;并且R2是氢、低级烷基、环烷基、(环烷基)烷基、苯基、取代的苯基、苯基烷基、取代的苯基烷基、萘基、取代的萘基、(1-或2-萘基)烷基或取代的(1-或2-萘基)烷基;并且其中:R1a和R1b独立地是氢、烷基、环烷基、(环烷基)烷基、苯基、取代的苯基、苯基烷基、取代的苯基烷基、萘基、取代的萘基、(1-或2-萘基)烷基、取代的(1-或2-萘基)烷基、杂芳基、取代的杂芳基、(杂芳基)烷基,或取代的(杂芳基)烷基,条件是R1a和R1b不都是氢;R1c是烷基、环烷基、(环烷基)烷基、苯基、取代的苯基、苯基烷基、取代的苯基烷基、萘基、取代的萘基、(1-或2-萘基)烷基、取代的(1-或2-萘基)烷基、杂芳基、取代的杂芳基、(杂芳基)烷基,或取代的(杂芳基)烷基;R3是C1-6低级烷基、环烷基、苯基、取代的苯基、(CH2)nNH2、(CH2)nNHCOR9、(CH2)nN(C=NH)NH2、(CH2)mCO2R2、(CH2)mOR10、(CH2)mSR11、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)或(CH2)n(杂芳基),其中杂芳基包括吡啶基、噻吩基、呋喃基、噻唑基、咪唑基、吡唑基、异噁唑基、吡嗪基、嘧啶基、三嗪基、四唑基和吲哚基;R3a是氢或甲基,或者R3和R3a一起是-(CH2)d-,其中d是2-6的整数;R4是苯基、取代的苯基、(CH2)m苯基、(CH2)m(取代的苯基)、环烷基或苯并稠合的环烷基;R5是氢、低级烷基、环烷基、苯基、取代的苯基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R6是氢、氟、氧代、低级烷基、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)、OR10、SR11或NHCOR9;R7是氢、氧代、低级烷基、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R8是低级烷基、环烷基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)或COR9;R9是氢、低级烷基、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)、OR12或NR13R14;R10是氢、低级烷基、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R11是低级烷基、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R12是低级烷基、环烷基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R13是氢、低级烷基、环烷基、苯基、取代的苯基、萘基、取代的萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);R14是氢或低级烷基;或者R13和R14一起形成五至七元碳环或杂环,例如吗啉或N-取代的哌嗪;R15是苯基、取代的苯基、萘基、取代的萘基、杂芳基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)或(CH2)n(杂芳基);R16和R17独立地是低级烷基、环烷基、苯基、取代的苯基、萘基、苯基烷基、取代的苯基烷基或(环烷基)烷基;R18和R19独立地是氢、烷基、苯基、取代的苯基、(CH2)n苯基、(CH2)n(取代的苯基),或R18和R19一起是-(CH=CH2)-;R20是氢、烷基、苯基、取代的苯基、(CH2)n苯基、(CH2)n(取代的苯基);R21、R22和R23独立地是氢或烷基;X是CH2、(CH2)2、(CH2)3或S;Y1是O或NR23;Y2是CH2、O或NR23;a是0或1并且b是1或2,条件是当a是1时,则b是1;c是1或2,条件是当c是1时,则a是0并且b是1;m是1或2;并且n是1、2、3或4。
- 2、权利要求1的化合物,其中A是
- 3、权利要求2的化合物,其中R3是低级烷基、环烷基、苯基、取代的苯基、(CH2)nNH2、(CH2)mOR10、(CH2)mSR11、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)或(CH2)n(1-或2-萘基);并且R3a是氢。
- 4、权利要求1的化合物,其中A是
- 5、权利要求4的化合物,其中R4是苯基、取代的苯基、(CH2)m苯基、(CH2)m(取代的苯基)、环烷基或2-二氢化茚基。
- 6、权利要求1的化合物,其中A是
- 7、权利要求6的化合物,其中R6是氢、氟、环烷基、苯基、取代的苯基、萘基、(CH2)n环烷基、(CH2)n苯基、(CH2)n(取代的苯基)、(CH2)n(1-或2-萘基)、OR10或SR11。
- 9、权利要求8的化合物,其中R7是氢、氧代、环烷基、苯基、取代的苯基或萘基;并且X=CH2、(CH2)2、(CH2)3或S。
- 11、权利要求10的化合物,其中a是0。
- 12、权利要求1的化合物,其中B是氢、2-苯并噁唑基、取代的2-噁唑基、CH2ZR15、CH2OCO(芳基)或CH2OPO(R16)R17,其中Z是氧或硫原子。
- 14、权利要求13的化合物,其中R18和R19独立地是氢、烷基或苯基,或者R18和R19一起是-(CH=CH)2-。
- 15、权利要求1的化合物,其中R1是苯基、取代的苯基、苯基烷基、取代的苯基烷基、萘基、取代的萘基、(1-或2-萘基)烷基、杂芳基或(杂芳基)烷基。
- 16、权利要求3的化合物,其中R3是甲基、异丙基、异丁基、环己基甲基、叔丁基、环己基或苯基。
- 17、权利要求16的化合物,其中B是CH2O(2,3,5,6-四氟苯基)。
- 18、权利要求1的化合物,其中R1是1-萘基并且A是缬氨酸。
- 19、权利要求1的化合物,其中R1是1-萘基并且B是CH2O(2,3,5,6-四氟苯基)。
- 20、一种药物组合物,含有权利要求1的化合物与可药用载体。
- 21、一种治疗自身免疫病的方法,包括给需此治疗的患者施用有效量的权利要求20的药物组合物。
- 22、一种治疗炎性疾病的方法,包括给需此治疗的患者施用有效量的权利要求20的药物组合物。
- 23、一种治疗神经变性疾病的方法,包括给需此治疗的患者施用有效量的权利要求20的药物组合物。
- 24、一种预防患与局部缺血性损伤相关疾病的患者局部缺血性损伤的方法,包括给需此治疗的患者施用有效量的权利要求20的药物组合物。
- 25、一种扩增造血细胞群体和/或提高其存活性的方法,包括使所述细胞与有效量的权利要求20的药物组合物接触。
- 26、权利要求25的方法,所述细胞群体是用于细胞转输的粒细胞、单核细胞、红细胞、淋巴细胞和血小板。
- 27、一种延长从供体取出的、用于进一步移植过程的器官或从器官上得到分离细胞的存活性的方法,该方法包括对所述器官或分离细胞应用有效量的权利要求20的药物组合物,由此与未处理的器官相比延长所述器官或分离细胞的存活性。
- 28、权利要求27的方法,其中所述的器官是一个完整的器官。
- 29、权利要求27的方法,其中所述的分离细胞是胰腺胰岛细胞、多巴胺能神经元、血细胞或造血细胞。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9168998P | 1998-07-02 | 1998-07-02 | |
US09/177,549 US6197750B1 (en) | 1998-07-02 | 1998-10-22 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US09/177,549 | 1998-10-22 | ||
US60/091,689 | 1998-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1313846A true CN1313846A (zh) | 2001-09-19 |
CN1159289C CN1159289C (zh) | 2004-07-28 |
Family
ID=26784233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998100196A Expired - Lifetime CN1159289C (zh) | 1998-07-02 | 1999-07-01 | 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 |
Country Status (23)
Country | Link |
---|---|
US (1) | US6197750B1 (zh) |
EP (2) | EP1091930B1 (zh) |
JP (1) | JP3815968B2 (zh) |
KR (1) | KR100804432B1 (zh) |
CN (1) | CN1159289C (zh) |
AT (2) | ATE442843T1 (zh) |
AU (1) | AU752339B2 (zh) |
BR (1) | BR9911675A (zh) |
CA (1) | CA2336474C (zh) |
CY (1) | CY1108088T1 (zh) |
DE (2) | DE69941440D1 (zh) |
DK (2) | DK1091930T3 (zh) |
ES (2) | ES2330663T3 (zh) |
HK (1) | HK1036616A1 (zh) |
HU (1) | HUP0102898A3 (zh) |
ID (1) | ID28263A (zh) |
IL (1) | IL140554A0 (zh) |
MX (1) | MXPA00013014A (zh) |
NO (1) | NO20006544L (zh) |
NZ (1) | NZ509025A (zh) |
PL (1) | PL207578B1 (zh) |
PT (1) | PT1091930E (zh) |
WO (1) | WO2000001666A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101573328A (zh) * | 2006-12-06 | 2009-11-04 | 辉瑞有限公司 | (3s)-3-[n-(n’-(2-叔丁基苯基)草氨酰基)丙氨酰基]氨基-5-(2’,3’,5’,6’-四氟苯氧基)-4-氧代戊酸的结晶形式 |
WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
WO2019174589A1 (zh) * | 2018-03-13 | 2019-09-19 | 正大天晴药业集团股份有限公司 | 一种Caspase抑制剂的结晶 |
CN113354708B (zh) * | 2017-01-23 | 2024-05-14 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1647279A3 (en) * | 1996-09-12 | 2006-04-26 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors |
US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
DE69939689D1 (de) * | 1998-03-19 | 2008-11-20 | Vertex Pharma | Caspase inhibitoren |
US6544951B2 (en) | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
MXPA01010127A (es) | 1999-04-09 | 2002-08-20 | Cytovia Inc | Inhibidores de la caspasa y el uso de los mismos. |
BR0013666A (pt) | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
WO2001044214A1 (fr) * | 1999-12-03 | 2001-06-21 | Ono Pharmaceutical Co., Ltd. | Derives d'oxadiazole et medicaments contenant ces derives utiles comme ingredients actifs |
US6515173B1 (en) | 2000-01-13 | 2003-02-04 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6790989B2 (en) * | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6867299B2 (en) | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
US6525024B1 (en) | 2000-04-17 | 2003-02-25 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
AU2001253633A1 (en) * | 2000-04-17 | 2001-10-30 | Idun Pharmaceuticals, Inc. | Inhibitors of the ice/ced-3 family of cysteine proteases |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
AU2002245649A1 (en) * | 2001-03-02 | 2002-09-19 | Idun Pharmaceuticals, Inc. | Methods, compositions and kits for preserving antigenicity |
EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
EP1485107A1 (en) * | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
EP1499898A2 (en) * | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
JP2006503852A (ja) * | 2002-09-25 | 2006-02-02 | ユニバーシティー オブ ロチェスター | 抗癌薬としてのカスパーゼインヒビター |
EP1583726A4 (en) * | 2002-10-09 | 2009-06-10 | Activx Biosciences Inc | EFFECT-BASED PROBES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
AU2004270733B2 (en) * | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
JP2007510931A (ja) * | 2003-11-10 | 2007-04-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Il−18をモニターするための方法 |
KR101135765B1 (ko) | 2004-03-12 | 2012-04-23 | 버텍스 파마슈티칼스 인코포레이티드 | 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체 |
EP2295054A1 (en) | 2004-05-27 | 2011-03-16 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
ATE543803T1 (de) | 2004-11-24 | 2012-02-15 | Vertex Pharma | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren |
EP1904100A1 (en) * | 2005-07-11 | 2008-04-02 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
CA2616337A1 (en) * | 2005-07-28 | 2007-02-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
US20140309172A1 (en) | 2010-11-05 | 2014-10-16 | Dagmar Ringe | Ice inhibiting compounds and uses thereof |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
EP4218829A3 (en) | 2013-03-15 | 2023-08-16 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
WO2015175381A1 (en) | 2014-05-12 | 2015-11-19 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitors |
EP3265440A1 (en) | 2015-03-06 | 2018-01-10 | Concert Pharmaceuticals Inc. | Deuterated emricasan |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
KR20180101418A (ko) | 2015-12-31 | 2018-09-12 | 코나터스 파마슈티칼스, 인크. | 간 질환의 치료에서의 카스파제 억제제의 사용 방법 |
CA3039283A1 (en) | 2016-10-05 | 2018-04-12 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
EP4310504A3 (en) | 2016-12-23 | 2024-05-01 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
EP3814327A1 (en) | 2018-06-29 | 2021-05-05 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
CA2122227A1 (en) | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
US5869519A (en) * | 1996-12-16 | 1999-02-09 | Idun Pharmaceuticals, Inc. | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US5968927A (en) * | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
US5877197A (en) * | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
-
1998
- 1998-10-22 US US09/177,549 patent/US6197750B1/en not_active Expired - Lifetime
-
1999
- 1999-07-01 AU AU48569/99A patent/AU752339B2/en not_active Expired
- 1999-07-01 EP EP99932211A patent/EP1091930B1/en not_active Expired - Lifetime
- 1999-07-01 AT AT06125650T patent/ATE442843T1/de not_active IP Right Cessation
- 1999-07-01 NZ NZ509025A patent/NZ509025A/en not_active Application Discontinuation
- 1999-07-01 DE DE69941440T patent/DE69941440D1/de not_active Expired - Lifetime
- 1999-07-01 ID IDW20010254A patent/ID28263A/id unknown
- 1999-07-01 DK DK99932211T patent/DK1091930T3/da active
- 1999-07-01 PT PT99932211T patent/PT1091930E/pt unknown
- 1999-07-01 BR BR9911675-8A patent/BR9911675A/pt not_active IP Right Cessation
- 1999-07-01 AT AT99932211T patent/ATE348096T1/de active
- 1999-07-01 WO PCT/US1999/015074 patent/WO2000001666A1/en active IP Right Grant
- 1999-07-01 MX MXPA00013014A patent/MXPA00013014A/es active IP Right Grant
- 1999-07-01 ES ES06125650T patent/ES2330663T3/es not_active Expired - Lifetime
- 1999-07-01 DK DK06125650T patent/DK1754475T3/da active
- 1999-07-01 PL PL345350A patent/PL207578B1/pl not_active IP Right Cessation
- 1999-07-01 EP EP06125650A patent/EP1754475B1/en not_active Expired - Lifetime
- 1999-07-01 DE DE69934405T patent/DE69934405T2/de not_active Expired - Lifetime
- 1999-07-01 HU HU0102898A patent/HUP0102898A3/hu unknown
- 1999-07-01 ES ES99932211T patent/ES2276520T3/es not_active Expired - Lifetime
- 1999-07-01 CN CNB998100196A patent/CN1159289C/zh not_active Expired - Lifetime
- 1999-07-01 IL IL14055499A patent/IL140554A0/xx not_active IP Right Cessation
- 1999-07-01 KR KR1020007015074A patent/KR100804432B1/ko not_active IP Right Cessation
- 1999-07-01 CA CA002336474A patent/CA2336474C/en not_active Expired - Lifetime
- 1999-07-01 JP JP2000558071A patent/JP3815968B2/ja not_active Expired - Lifetime
-
2000
- 2000-12-21 NO NO20006544A patent/NO20006544L/no unknown
-
2001
- 2001-10-18 HK HK01107291A patent/HK1036616A1/xx not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100251T patent/CY1108088T1/el unknown
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101573328B (zh) * | 2006-12-06 | 2014-04-02 | 科内图斯医药公司 | (3s)-3-[n-(n'-(2-叔丁基苯基)草氨酰基)丙氨酰基]氨基-5-(2',3',5',6'-四氟苯氧基)-4-氧代戊酸的结晶形式 |
CN103951583A (zh) * | 2006-12-06 | 2014-07-30 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
CN103951583B (zh) * | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
CN103923169B (zh) * | 2006-12-06 | 2017-05-24 | 科内图斯医药公司 | (3s)‑3‑[n‑(n’‑(2‑叔丁基苯基)草氨酰基)丙氨酰基]氨基‑5‑(2’,3’,5’,6’‑四氟苯氧基)‑4‑氧代戊酸的结晶形式 |
CN101573328A (zh) * | 2006-12-06 | 2009-11-04 | 辉瑞有限公司 | (3s)-3-[n-(n’-(2-叔丁基苯基)草氨酰基)丙氨酰基]氨基-5-(2’,3’,5’,6’-四氟苯氧基)-4-氧代戊酸的结晶形式 |
TWI764977B (zh) * | 2017-01-23 | 2022-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 作爲caspase抑制劑的聯環化合物、含有其的藥物組合物及其應用 |
WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN110177774A (zh) * | 2017-01-23 | 2019-08-27 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN113354708B (zh) * | 2017-01-23 | 2024-05-14 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN110177774B (zh) * | 2017-01-23 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
US11434212B2 (en) | 2017-01-23 | 2022-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicyclic compound as a caspase inhibitor |
CN113354708A (zh) * | 2017-01-23 | 2021-09-07 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN111757871A (zh) * | 2018-03-13 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种Caspase抑制剂的结晶 |
CN111757871B (zh) * | 2018-03-13 | 2022-04-12 | 正大天晴药业集团股份有限公司 | 一种Caspase抑制剂的结晶 |
US11091450B2 (en) | 2018-03-13 | 2021-08-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of a caspase inhibitor |
WO2019174589A1 (zh) * | 2018-03-13 | 2019-09-19 | 正大天晴药业集团股份有限公司 | 一种Caspase抑制剂的结晶 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1313846A (zh) | 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽 | |
CN1134264C (zh) | 抗血栓形成剂 | |
CN1207056C (zh) | 含肽的α-酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂 | |
US20030232788A1 (en) | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | |
CN1198096A (zh) | 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂 | |
EP1123272A1 (en) | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | |
CN1549717A (zh) | 用于治疗炎症和其它疾病、具有2-氰基-4-氨基嘧啶结构和组织蛋白酶k抑制活性的半胱氨酸蛋白酶抑制剂 | |
CN1378450A (zh) | 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法 | |
CN1261277A (zh) | 新的取代咪唑化合物 | |
CN1205328A (zh) | 磺酰氨基羧酸 | |
US20060084613A1 (en) | Inhibitors of the ICE/ced-3 family of cysteine proteases | |
CN1525978A (zh) | 用作ICE/ced-3家族半胱氨酸蛋白酶抑制剂的C-端修饰的草氨酰二肽 | |
CN1127488C (zh) | 具有生长激素释放特性的化合物 | |
CN1349542A (zh) | 杂环化合物、其中间体和弹性蛋白酶抑制剂 | |
CN1017622B (zh) | 茚满衍生物的制备方法 | |
US6544951B2 (en) | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | |
US7157430B2 (en) | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases | |
CN1396909A (zh) | ICE/ced-3族的半胱氨酸蛋白酶的抑制剂 | |
KR100565008B1 (ko) | 4-하이드라지노-3-사이클로부텐-1,2-다이온 유도체 및이들의 제조 방법 | |
CN1207101A (zh) | 抑制酶中ice/ced-3蛋白酶类的新三环化合物 | |
CN1660811A (zh) | 1,4-二取代苯类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KANGNATAS PHARMACEUTICALS, INC. Free format text: FORMER OWNER: IDUN PHARMACEUTICALS LTD. Effective date: 20130802 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130802 Address after: American California Patentee after: Connor, Tasmania pharmaceuticals, Limited by Share Ltd Address before: American California Patentee before: Idum Pharmaceuticals, Inc. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040728 |